Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer.

[1]  S. Veronese,et al.  Mutations of KRAS and BRAF in primary and matched metastatic sites of colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Peeters,et al.  Review article: panitumumab ‐ a fully human anti‐EGFR monoclonal antibody for treatment of metastatic colorectal cancer , 2008, Alimentary pharmacology & therapeutics.

[3]  M. Raponi,et al.  KRAS mutations predict response to EGFR inhibitors. , 2008, Current opinion in pharmacology.

[4]  H. Wasan,et al.  Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial , 2008, Expert review of anticancer therapy.

[5]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[6]  Pierre Laurent-Puig,et al.  Mutations in the RAS‐MAPK, PI(3)K (phosphatidylinositol‐3‐OH kinase) signaling network correlate with poor survival in a population‐based series of colon cancers , 2008, International journal of cancer.

[7]  D. Khayat,et al.  Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. , 2008, Critical reviews in oncology/hematology.

[8]  Daniel J. Freeman,et al.  Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  G. Tortora,et al.  EGFR antagonists in cancer treatment. , 2008, The New England journal of medicine.

[10]  A. Lièvre,et al.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  P. Jares,et al.  KRAS mutation testing for predicting response to anti-EGFR therapy for colorectal carcinoma: proposal for an European quality assurance program , 2008, Virchows Archiv.

[12]  R. Schneider-Stock,et al.  K-ras mutation detection in colorectal cancer using the Pyrosequencing technique. , 2007, Pathology, research and practice.

[13]  T. Frebourg,et al.  Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy , 2007, British Journal of Cancer.

[14]  A. Lièvre,et al.  KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. , 2006, Cancer research.

[15]  M. Loda,et al.  Sensitive sequencing method for KRAS mutation detection by Pyrosequencing. , 2005, The Journal of molecular diagnostics : JMD.

[16]  H. Lane,et al.  ERBB Receptors and Cancer: The Complexity of Targeted Inhibitors , 2005, Nature Reviews Cancer.

[17]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia , 2003, Nature Genetics.

[18]  E. Sausville,et al.  Issues and progress with protein kinase inhibitors for cancer treatment , 2003, Nature Reviews Drug Discovery.

[19]  R. Goldbohm,et al.  K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. , 2003, Carcinogenesis.

[20]  J. Licht,et al.  Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leykemia , 2003, Nature Genetics.

[21]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[22]  H. Barrera-Saldana,et al.  Frequency and Clinicopathology Associations of K-ras Mutations in Colorectal Cancer in a Northeast Mexican Population , 2000, Digestive Diseases.

[23]  F. Al-Mulla,et al.  Heterogeneity of mutant versus wild‐type Ki‐ras in primary and metastatic colorectal carcinomas, and association of codon‐12 valine with early mortality , 1998, The Journal of pathology.

[24]  A. Norman,et al.  Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. , 1998, Journal of the National Cancer Institute.

[25]  A. Børresen-Dale,et al.  Ki-ras mutations and prognosis in colorectal cancer. , 1998, European journal of cancer.

[26]  J. Benhattar,et al.  The type of K-ras mutation determines prognosis in colorectal cancer. , 1998, American journal of surgery.

[27]  J. Arends,et al.  A detailed analysis of K‐ras point mutations in relation to tumor progression and survival in colorectal cancer patients , 1996, International journal of cancer.

[28]  J. Arends,et al.  Type and number of Ki-ras point mutations relate to stage of human colorectal cancer. , 1994, Cancer research.

[29]  S. Knežević-Ušaj,et al.  Prevalence of G‐TO‐T transversions among K‐ras oncogene mutations in human colorectal tumors in Yugoslavia , 1993, International journal of cancer.

[30]  H. Rabes,et al.  K‐ras point mutations in human colorectal carcinomas: Relation to aneuploidy and metastasis , 1992, International journal of cancer.

[31]  S. Rodenhuis,et al.  Differential activation of ras genes by point mutation in human colon cancer with metastases to either lung or liver , 1991, International journal of cancer.